ALXN1840 Rolling NDA Masks Critical Evidence Gaps That Could Undermine Premium Market Access

Monopar Initiates Rolling NDA for ALXN1840 and Reports Q2 2026 Results

Monopar Therapeutics Inc. announced its second quarter 2026 financial results and provided business updates, primarily focusing on ALXN1840 for Wilson disease. Key developments include the initiation of a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for ALXN1840, which also received Rare Pediatric Disease (RPD) designation. The company presented new analyses from the Phase 3 FoCus trial and Phase 2 data at major conferences, demonstrating significant neurologic improvement, stabilization of liver disease, and improved copper balance. Monopar reported a net loss of $5.3 million for Q2 2026 and expects current funds to support operations through at least December 31, 2027.

• Monopar initiated a rolling NDA submission for ALXN1840 to the FDA on July 22, 2026, following the FDA's authorization. This allows for sections of the application to be submitted and reviewed as they are completed, with full submission anticipated within months. Additionally, ALXN1840 received Rare Pediatric Disease (RPD) designation on June 30, 2026, which could lead to a pediatric Priority Review Voucher (PRV) upon NDA approval, offering potential for expedited review of a subsequent marketing application or transferability.
• New analyses from the Phase 3 FoCus trial of ALXN1840 were presented at the 12th Congress of the European Academy of Neurology (EAN 2026) and the American Academy of Neurology (AAN) Annual Meeting. These presentations highlighted significant neurologic improvement and greater global clinical improvement with ALXN1840 compared to standard-of-care in Wilson disease patients with neurologic symptoms. Furthermore, Phase 2 data presented at EASL Congress 2026 showed ALXN1840 stabilized liver disease and improved neurological symptoms and quality of life in heavily pre-treated patients.
• For the second quarter of 2026, Monopar reported a net loss of $5.3 million, an increase from $2.5 million in Q2 2025, primarily due to increased R&D and G&A expenses. Cash, cash equivalents, and investments stood at $134.3 million as of June 30, 2026, projected to fund operations through at least December 31, 2027. The company is also strengthening its commercial readiness for ALXN1840, with key leadership appointments including a Chief Commercial and Strategy Officer and additions to the Board and commercial team.

Benchmarking ALXN1840: Current Standard of Care in Wilson Disease

Wilson disease management is guided by lifelong pharmacotherapy aimed at reducing pathological copper accumulation, with treatment selection dictated by disease presentation, severity, and patient-specific factors. Chelating agents — principally D-penicillamine and trientine — constitute the cornerstone of first-line therapy for symptomatic patients, with both agents demonstrating comparable clinical outcomes. However, due to the frequent adverse effects associated with D-penicillamine and its propensity to precipitate initial neurological deterioration, the less toxic alternatives trientine and zinc have progressively supplanted penicillamine in clinical practice. For neurological Wilson disease specifically, trientine or tetrathiomolybdate is increasingly favored as the preferred first-line intervention. Zinc salts, by contrast, are recommended as monotherapy for asymptomatic or presymptomatic patients, and as maintenance therapy following long-term chelation, with both applications supported by established safety and efficacy data. Zinc monotherapy may also be considered in oligosymptomatic patients, though elevated baseline 24-hour urinary copper excretion can portend treatment failure in this setting.

Treatment stratification is further refined by clinical presentation. Chelation therapy is reserved for patients with severe hepatic involvement, while liver transplantation is clearly indicated in the context of acute liver failure but is not recommended as a primary therapeutic strategy for neurological disease. Diagnosis is standardized through the Leipzig scoring system, supplemented by exchangeable copper measurements, and supported by biochemical parameters including plasma ceruloplasmin, 24-hour urinary copper, and hepatic copper content, alongside molecular genetic analysis.

Longitudinal monitoring remains integral to disease management and is conducted at minimum on a biannual basis in the majority of treating centers. Surveillance is anchored to clinical symptomatology, hepatic biochemical indices, and copper metabolism markers — particularly 24-hour urinary copper and exchangeable copper — enabling identification of both treatment non-adherence and instances of over- or under-treatment. In pregnancy, dose reduction of chelator therapy is practiced across a subset of departments, though the proportion recommending formal dose reduction remains limited.

ALXN1840: A New Horizon for Wilson Disease Management

The ongoing development and regulatory progress of ALXN1840 for Wilson disease mark a pivotal moment for patients grappling with this debilitating genetic disorder. Current therapeutic mainstays, including copper chelators like D-penicillamine and zinc salts, have provided relief for many, yet significant challenges persist. Studies indicate that D-penicillamine, while effective, can paradoxically worsen neurological symptoms in a substantial portion of patients, affecting over 30%. Furthermore, zinc monotherapy has shown to be less effective in preventing hepatic deterioration compared to chelating agents, highlighting a critical unmet need for safer and more consistently effective treatments.

ALXN1840, a novel bis-choline tetrathiomolybdate, offers a distinct approach. Research suggests it rapidly lowers toxic non-ceruloplasmin-bound copper levels and has been associated with improved neurological status without the initial drug-induced worsening seen with some older therapies. This is particularly significant given its potential to prevent copper-induced blood-brain barrier damage. The initiation of a rolling New Drug Application submission and the receipt of Rare Pediatric Disease designation underscore the urgency and potential for this therapy to address critical gaps in care.

However, as with any emerging therapy, important considerations remain:

• While animal models suggested ALXN1840 promotes biliary copper excretion, human studies have surprisingly indicated its primary action might be through reducing intestinal copper uptake and retaining copper in the bloodstream. This nuanced understanding of its mechanism in humans will be crucial for optimizing its use.

• The long-term efficacy and safety of ALXN1840, especially when compared to the extensive real-world data available for established treatments, will need continued evaluation to ensure sustained benefits in preventing both hepatic and neurological progression over a patient's lifetime.

• Patient heterogeneity in Wilson disease means that while ALXN1840 shows broad promise, its specific effectiveness and safety profile across all patient subgroups, particularly those with severe chronic liver disease or specific genetic mutations, will require careful monitoring.

Ultimately, ALXN1840 has the potential to redefine treatment standards for Wilson disease, offering a much-needed alternative that could mitigate some of the severe side effects and limitations of current therapies. Its journey through regulatory review will be closely watched by the clinical community, holding the promise of a new era in managing this complex condition.